NASDAQ:DRRX

DURECT (DRRX) Stock Forecast, Price & News

$2.63

-0.06 (-2.23%)

(As of 09/26/2023 ET)

Compare

Today's Range: $2.57
▼
$2.84
50-Day Range: $2.63
▼
$4.92
52-Week Range: $2.57
▼
$9.50

Volume: 631,590 shs
Average Volume: 160,692 shs
Market Capitalization: $72.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.25

DURECT MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,202.3% Upside
$34.25 Price Target
Short Interest: Bearish
7.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.19
Upright™ Environmental Score
News Sentiment: 1.25
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.76) to ($1.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

569th out of 964 stocks

Pharmaceutical Preparations Industry

252nd out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
DURECT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.25, DURECT has a forecasted upside of 1,202.3% from its current price of $2.63.
Amount of Analyst Coverage
DURECT has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.99% of the float of DURECT has been sold short.
Short Interest Ratio / Days to Cover
DURECT has a short interest ratio ("days to cover") of 9.7.
Change versus previous month
Short interest in DURECT has recently increased by 19.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
DURECT does not currently pay a dividend.
Dividend Growth
DURECT does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
DURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for DURECT is -1.19.

3.5

News and Social Media Coverage

News Sentiment
DURECT has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for DURECT this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
6 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DURECT insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of DURECT is held by insiders.
Percentage Held by Institutions
Only 32.82% of the stock of DURECT is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for DURECT are expected to grow in the coming year, from ($1.76) to ($1.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DURECT is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DURECT is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DURECT has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About DURECT (NASDAQ:DRRX) Stock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Price History

30 days | 90 days | 365 days | Advanced Chart

DRRX Stock News Headlines

September 18, 2023 | americanbankingnews.com

DURECT Co. (NASDAQ:DRRX) Forecasted to Earn Q3 2023 Earnings of ($0.42) Per Share

September 17, 2023 | americanbankingnews.com

Short Interest in DURECT Co. (NASDAQ:DRRX) Rises By 19.2%

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

September 17, 2023 | americanbankingnews.com

DURECT (NASDAQ:DRRX) Rating Lowered to Sell at StockNews.com

September 14, 2023 | msn.com

Northland sees DURECT's upcoming data as "major" catalyst for stock

September 14, 2023 | seekingalpha.com

Northland sees DURECT's upcoming data as "major" catalyst for stock (update)

September 7, 2023 | finance.yahoo.com

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

August 31, 2023 | finance.yahoo.com

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Durect (DRRX) and Cytokinetics (CYTK)

August 11, 2023 | msn.com

Cantor Fitzgerald Maintains Durect (DRRX) Overweight Recommendation

August 11, 2023 | msn.com

HC Wainwright & Co. Maintains Durect (DRRX) Buy Recommendation

August 9, 2023 | msn.com

DURECT GAAP EPS of -$0.46 beats by $0.02, revenue of $2.08M misses by $1.08M

August 9, 2023 | finance.yahoo.com

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

August 8, 2023 | benzinga.com

Earnings Outlook For Durect

August 3, 2023 | finance.yahoo.com

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

July 20, 2023 | msn.com

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.47%

July 20, 2023 | marketwatch.com

Durect Shares Slide Premarket on Planned Stock Sale >DRRX

July 20, 2023 | finance.yahoo.com

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

June 7, 2023 | finance.yahoo.com

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

May 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Pfizer (PFE) and BioVie (BIVI)

May 17, 2023 | msn.com

Cantor Fitzgerald Reiterates Durect (DRRX) Overweight Recommendation

May 17, 2023 | markets.businessinsider.com

Analyst Ratings for Durect

May 17, 2023 | marketwatch.com

8-K: DURECT CORP

May 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Durect (DRRX), MacroGenics (MGNX) and Precision BioSciences (DTIL)

May 11, 2023 | finance.yahoo.com

Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet

May 10, 2023 | washingtonpost.com

Durect: Q1 Earnings Snapshot

See More Headlines

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Company Calendar

Last Earnings: 8/09/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DRRX
CUSIP: N/A
CIK: 1082038
Web: www.durect.com
Phone: (408) 777-1417
Fax: 408-777-3577
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.25
High Stock Price Forecast: $41.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +1,202.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,330,000.00
Net Margins: -185.87%
Pretax Margin: -185.87%
Return on Equity: -179.02%
Return on Assets: -61.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.97
Quick Ratio: 0.92

Sales & Book Value

Annual Sales: $19.28 million
Price / Sales: 3.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.10 per share
Price / Book: 2.39

Miscellaneous

Outstanding Shares: 27,600,000
Free Float: 26,413,000
Market Cap: $72.59 million
Optionable: Optionable
Beta: 1.49

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. James E. Brown D.V.M. (Age 66)
Co-Founder, CEO, Pres & Director
Comp: $885.86k

Ms. Judy R. Joice (Age 66)
Sr. VP of Operations & Corp. Quality Assurance
Comp: $451.82k

Dr. Norman L. Sussman M.D. (Age 70)
Chief Medical Officer
Comp: $587.95k

Mr. Timothy M. Papp M.B.A. (Age 47)
CFO & Sec.

Ms. Jian Li M.B.A. (Age 53)
Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.

Dr. WeiQi Lin M.D.
Ph.D., Exec. VP of R&D and Principal Scientist

Mr. Keith L. Lui M.B.A.
Sr. VP of Bus. Devel., Commercial & Medical Affairs

Dr. Su Il Yum Ph.D. (Age 84)
Exec. Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DRRX Stock - Frequently Asked Questions

Should I buy or sell DURECT stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRRX shares.
View DRRX analyst ratings or view top-rated stocks.
What is DURECT's stock price forecast for 2023?: 4 brokerages have issued twelve-month price targets for DURECT's shares. Their DRRX share price forecasts range from $27.00 to $41.00. On average, they anticipate the company's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 1,202.3% from the stock's current price.
View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts.
How have DRRX shares performed in 2023?: DURECT's stock was trading at $3.46 at the beginning of 2023. Since then, DRRX stock has decreased by 24.0% and is now trading at $2.63.
View the best growth stocks for 2023 here.
When is DURECT's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our DRRX earnings forecast.
How were DURECT's earnings last quarter?: DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Wednesday, August, 9th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.01. The specialty pharmaceutical company earned $2.08 million during the quarter, compared to analyst estimates of $2.89 million. DURECT had a negative net margin of 185.87% and a negative trailing twelve-month return on equity of 179.02%.
When did DURECT's stock split?: DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).
What is DURECT's stock symbol?: DURECT trades on the NASDAQ under the ticker symbol "DRRX."
Who are DURECT's major shareholders?: DURECT's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (6.10%), CM Management LLC (1.92%), Renaissance Technologies LLC (1.48%), BlackRock Inc. (1.46%), Beirne Wealth Consulting Services LLC (1.15%) and Geode Capital Management LLC (0.95%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito.
View institutional ownership trends.
How do I buy shares of DURECT?: Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is DURECT's stock price today?: One share of DRRX stock can currently be purchased for approximately $2.63.
How much money does DURECT make?: DURECT (NASDAQ:DRRX) has a market capitalization of $72.59 million and generates $19.28 million in revenue each year. The specialty pharmaceutical company earns $-35,330,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.
How can I contact DURECT?: DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial